Get a weekly digest of the latest psychedelic research, new studies, and platform updates delivered to your inbox.
No spam, ever. Unsubscribe anytime.
Lifetime prevalence approximately 0.5-2% (predominantly female, increasingly diagnosed in males). Highest mortality rate of any psychiatric disorder (5-10% over 10 years).
Family-based therapy (FBT) for adolescents, CBT-E for adults, nutritional rehabilitation, weight restoration. No FDA-approved pharmacotherapy specifically for AN.
Psilocybin may disrupt the rigid cognitive patterns and distorted body image characteristic of AN by increasing cognitive flexibility and emotional processing.
Spriggs et al. (2021): Case series showed psilocybin reduced eating disorder psychopathology. COMP360 Phase 2 trial (Compass Pathways) enrolling for AN.